STAT+: Breast cancer pill from AstraZeneca misses mark in pivotal trial
A pill from AstraZeneca failed to improve outcomes in closely watched breast cancer study, a result that could limit the use of the medicine.
<p>A pill from AstraZeneca failed to improve outcomes in closely watched breast cancer study, a result that could limit the use of the medicine.</p>